Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults

被引:38
作者
Sukasem, Chonlaphat [1 ,2 ]
Cressey, Tim R. [3 ,4 ]
Prapaithong, Pattamawan [1 ]
Tawon, Yardpiroon [3 ]
Pasomsub, Ekawat [2 ]
Srichunrusami, Chutatip [2 ]
Jantararoungtong, Thawinee [1 ]
Lallement, Marc [3 ,4 ]
Chantratita, Wasun [2 ]
机构
[1] Mahidol Univ, Fac Med, Ramathibodi Hosp, Lab Pharmacogenom & Personalized Med, Bangkok 10400, Thailand
[2] Mahidol Univ, Fac Med, Ramathibodi Hosp, Lab Virol & Mol Microbiol,Dept Pathol, Bangkok 10400, Thailand
[3] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Program HIV Prevent & Treatment IRD URI 174, Chiang Mai 50000, Thailand
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
CYP2B6; efavirenz; HIV-1; pharmacogenetics; SNPs; Thailand; POPULATION PHARMACOKINETICS; TREATMENT FAILURE; POLYMORPHISMS; METABOLISM; IDENTIFICATION; PREDICTORS; EXPRESSION; VARIANT; IMPACT; GENE;
D O I
10.1111/j.1365-2125.2012.04288.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To investigate the frequency of CYP2B6 polymorphisms and the influence of haplotype structure on plasma efavirenz concentrations in Thai adults with HIV-1 infection. Methods Genotyping of nine single nucleotide polymorphisms (SNPs, c.64C>T, c.499C>G, c.516G>T, c.785A>G, c.1375A>G, c.1459C>T, g.3003T>C, g.18492C>T and g.21563C>T) of CYP2B6 were performed using real-time PCR-based allelic discrimination on blood samples from 52 HIV-infected adults who had received an efavirenz-based regimen. Plasma efavirenz concentrations were measured by high performance liquid chromatography. Results The minor allele frequencies for c.64C>T, c.516G>T, c.785A>G, g.3003C>T, g.18492T>C and g.21563C>T were 0.087, 0.365, 0.413, 0.308 and 0.356, respectively. However, no variant alleles were identified for three SNPs (c.499 C>G, c.1375 A>G and c.1459 C>T). Efavirenz plasma concentrations were significantly associated with c.516 G>T (P = 0.0095), c.785 A>G (P = 0.0017), g.21563 C>T (P = 0.0036) and g.18492 C>T (P = 0.0011). The composite CYP2B6 of three SNPs (c.516 G >= T, c.785 A >= G and g.21563 C >= T) genotypes were significantly associated with higher efavirenz concentrations. Conclusions Our data indicate that the GAC-CYP2B6 haplotype is associated with higher plasma efavirenz concentrations in HIV-infected Thai adults.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 28 条
[1]   Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients [J].
Cabrera, Salvador E. ;
Santos, Dolores ;
Valverde, Maria P. ;
Dominguez-Gil, Alfonso ;
Gonzalez, Francisco ;
Luna, Guillermo ;
Garcia, Maria J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) :2791-2798
[2]   Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort [J].
Carr, Daniel F. ;
la Porte, Charles J. L. ;
Pirmohamed, Munir ;
Owen, Andrew ;
Cortes, Claudia P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) :1889-1893
[3]   Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women [J].
Chantarangsu, Soranun ;
Cressey, Tim R. ;
Mahasirimongkol, Surakameth ;
Capparelli, Edmund ;
Tawon, Yardpiroon ;
Ngo-Giang-Huong, Nicole ;
Jourdain, Gonzague ;
Lallemant, Marc ;
Chantratita, Wasun .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (06) :1265-1273
[4]   CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients [J].
Chen, Jun ;
Sun, Jianjun ;
Ma, Qing ;
Yao, Yaming ;
Wang, Zhenyan ;
Zhang, Lijun ;
Li, Li ;
Sun, Fuyan ;
Lu, Hongzhou .
THERAPEUTIC DRUG MONITORING, 2010, 32 (05) :573-578
[5]   Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo [J].
Colombo, S ;
Soranzo, N ;
Rotger, M ;
Sprenger, R ;
Bleiber, G ;
Furrer, H ;
Buclin, T ;
Goldstein, D ;
Décosterd, L ;
Telenti, A .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) :599-608
[6]   Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection [J].
Csajka, C ;
Marzolini, C ;
Fattinger, K ;
Décosterd, LA ;
Fellay, J ;
Telenti, A ;
Biollaz, J ;
Buclin, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :20-30
[7]   Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro [J].
Desta, Zeruesenay ;
Saussele, Tanja ;
Ward, Bryan ;
Blievernicht, Julia ;
Li, Lang ;
Klein, Kathrin ;
Flockhart, DavidA ;
Zanger, Ulrich M. .
PHARMACOGENOMICS, 2007, 8 (06) :547-558
[8]   Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26 [J].
Gatanaga, Hiroyuki ;
Hayashida, Tsunefusa ;
Tsuchiya, Kiyoto ;
Yoshino, Munehiro ;
Kuwahara, Takeshi ;
Tsukada, Hiroki ;
Fujimoto, Katsuya ;
Sato, Isao ;
Ueda, Mikio ;
Horiba, Masahide ;
Hamaguchi, Motohiro ;
Yamamoto, Masahiro ;
Takata, Noboru ;
Kimura, Akiro ;
Koike, Takao ;
Gejyo, Fumitake ;
Matsushita, Shuzo ;
Shirasaka, Takuma ;
Kimura, Satoshi ;
Oka, Shinichi .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (09) :1230-1237
[9]  
Haas DW, 2004, AIDS, V18, P2391
[10]   CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients [J].
Kwara, Awewura ;
Lartey, Margaret ;
Sagoe, Kwamena W. C. ;
Kenu, Ernest ;
Court, Michael H. .
AIDS, 2009, 23 (16) :2101-2106